N Bansal1, C S Hampe2, L Rodriguez3, E O'Brian Smith4, J Kushner1, A Balasubramanyam5, M J Redondo1. 1. Department of Pediatrics, Section of Diabetes and Endocrinology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA. 2. Department of Medicine, University of Washington, Seattle, WA, USA. 3. Department of Pediatrics, Section of Pediatric Endocrinology, Children's Hospital of San Antonio, Baylor College of Medicine, San Antonio, TX, USA. 4. Children's Nutrition Research Center, Baylor College of Medicine, Houston, TX, USA. 5. Translational Metabolism Unit, Diabetes Research Center, Division of Diabetes, Endocrinology and Metabolism, Baylor College of Medicine, Houston, TX, USA.
Abstract
AIM: To study whether DPD epitope-specific glutamate decarboxylase autoantibodies are found more frequently in children with milder forms of Type 1 diabetes. METHODS: We prospectively evaluated 75 children with new-onset autoimmune Type 1 diabetes, in whom we collected demographic, anthropometric and clinical data and measured islet autoantibodies. Glutamate decarboxylase 65 autoantibody-positive samples were analysed for epitope specificities using recombinant Fab against the DPD-defined epitope of glutamate decarboxylase 65. RESULTS: After adjustment for age, positive DPD epitope recognition was significantly associated with higher C-peptide levels at onset (P = 0.02, r2 =0.21, n = 35), and high DPD recognition in the highest quartile tended to be associated with HbA1c ≤ 53 mmol/mol (7%) at the last follow-up [mean (sd) follow-up 1.3 (0.4) years; P = 0.07; for the model, P = 0.044, n = 30)]. Age- and sex-adjusted BMI percentile was significantly correlated with recognition of the DPD-defined epitope (P < 0.03, r2 =0.14, n = 34), but this correlation was driven by the older age group (age ≥ 10 years; P = 0.016, r2 =0.27, n = 21) and was not significant in younger children (P = 0.93, n = 13). There were no independent associations with sex, race/ethnicity, diabetic ketoacidosis, HbA1c , HLA DR3-DQ2/DR4-DQ8 or autoantibody number. CONCLUSIONS: Our findings suggest that recognition of the DPD-defined glutamate decarboxylase 65 autoantibody epitope at Type 1 diabetes onset is directly associated with β-cell function, BMI and age, which supports the hypothesis that immunological factors contribute to the clinical heterogeneity of Type 1 diabetes. Larger studies relating epitope-specific glutamate decarboxylase 65 autoantibody to clinical phenotype in children with Type 1 diabetes are warranted.
AIM: To study whether DPD epitope-specific glutamate decarboxylase autoantibodies are found more frequently in children with milder forms of Type 1 diabetes. METHODS: We prospectively evaluated 75 children with new-onset autoimmune Type 1 diabetes, in whom we collected demographic, anthropometric and clinical data and measured islet autoantibodies. Glutamate decarboxylase 65 autoantibody-positive samples were analysed for epitope specificities using recombinant Fab against the DPD-defined epitope of glutamate decarboxylase 65. RESULTS: After adjustment for age, positive DPD epitope recognition was significantly associated with higher C-peptide levels at onset (P = 0.02, r2 =0.21, n = 35), and high DPD recognition in the highest quartile tended to be associated with HbA1c ≤ 53 mmol/mol (7%) at the last follow-up [mean (sd) follow-up 1.3 (0.4) years; P = 0.07; for the model, P = 0.044, n = 30)]. Age- and sex-adjusted BMI percentile was significantly correlated with recognition of the DPD-defined epitope (P < 0.03, r2 =0.14, n = 34), but this correlation was driven by the older age group (age ≥ 10 years; P = 0.016, r2 =0.27, n = 21) and was not significant in younger children (P = 0.93, n = 13). There were no independent associations with sex, race/ethnicity, diabetic ketoacidosis, HbA1c , HLA DR3-DQ2/DR4-DQ8 or autoantibody number. CONCLUSIONS: Our findings suggest that recognition of the DPD-defined glutamate decarboxylase 65 autoantibody epitope at Type 1 diabetes onset is directly associated with β-cell function, BMI and age, which supports the hypothesis that immunological factors contribute to the clinical heterogeneity of Type 1 diabetes. Larger studies relating epitope-specific glutamate decarboxylase 65 autoantibody to clinical phenotype in children with Type 1 diabetes are warranted.
Authors: K Decochez; B Keymeulen; G Somers; H Dorchy; I H De Leeuw; C Mathieu; R Rottiers; F Winnock; K ver Elst; I Weets; L Kaufman; D G Pipeleers; F K Gorus Journal: Diabetes Care Date: 2000-08 Impact factor: 19.112
Authors: R J Kuczmarski; C L Ogden; L M Grummer-Strawn; K M Flegal; S S Guo; R Wei; Z Mei; L R Curtin; A F Roche; C L Johnson Journal: Adv Data Date: 2000-06-08
Authors: Shilpa Oak; Lisa K Gilliam; Mona Landin-Olsson; Carina Törn; Ingrid Kockum; Christina R Pennington; Merrill J Rowley; Michael R Christie; J Paul Banga; Christiane S Hampe Journal: Proc Natl Acad Sci U S A Date: 2008-03-26 Impact factor: 11.205
Authors: Gaya Thanabalasingham; Aparna Pal; Mary P Selwood; Christina Dudley; Karen Fisher; Polly J Bingley; Sian Ellard; Andrew J Farmer; Mark I McCarthy; Katharine R Owen Journal: Diabetes Care Date: 2012-03-19 Impact factor: 19.112
Authors: Sefina Arif; Pia Leete; Vy Nguyen; Katherine Marks; Nurhanani Mohamed Nor; Megan Estorninho; Deborah Kronenberg-Versteeg; Polly J Bingley; John A Todd; Catherine Guy; David B Dunger; Jake Powrie; Abby Willcox; Alan K Foulis; Sarah J Richardson; Emanuele de Rinaldis; Noel G Morgan; Anna Lorenc; Mark Peakman Journal: Diabetes Date: 2014-06-17 Impact factor: 9.461
Authors: Omaima M Sabek; Maria J Redondo; Duc T Nguyen; Christine A Beamish; Daniel W Fraga; Christiane S Hampe; Surya N Mulukutla; Edward A Graviss; A Osama Gaber Journal: Endocrinol Diabetes Metab Date: 2019-11-29
Authors: Scott J Pilla; Ashok Balasubramanyam; William C Knowler; Mariana Lazo; David M Nathan; Xavier Pi-Sunyer; Jeanne M Clark; Nisa M Maruthur Journal: Autoimmunity Date: 2019-01-02 Impact factor: 2.815